Browsing Tag
CAR-NK
2 posts
AACR 2026: Precision Biologics says it found a new weak spot in AML for CAR-NK therapy
Precision Biologics has revealed a new AML CAR-NK target at AACR 2026. Read why truncated O-glycans could matter for future leukemia therapy.
Senti Biosciences gets FDA orphan drug status for SENTI-202 in relapsed AML treatment
Senti Biosciences earns FDA orphan drug designation for SENTI-202 in AML. Find out how this logic-gated CAR-NK therapy could reshape leukemia treatment.